Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 236, Issue 11, 1998, Pages 811-821

  Kobelt, Gisela ^a   Jönsson, Linus ^b   Gerdtham, Ulf ^c   Krieglstein, Günter K ^d  

^a Health Dynamics International Ltd   (France)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; DORZOLAMIDE; LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MODEL; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SIMULATION;

ADRENERGIC BETA-ANTAGONISTS; CARBONIC ANHYDRASE INHIBITORS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GLAUCOMA, OPEN-ANGLE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INTRAOCULAR PRESSURE; MALE; MARKOV CHAINS; MIDDLE AGED; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 0031751109     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004170050165     Document Type: Article

References (25)

1. Alm A, Stjernschantz J, The Scandinavian Latanoprost Study Group (1995) Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology 102:1743-1752
2. Camras CB. The United States Latanoprost Study Group (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 103:138-147
3. Canadian Coordinating Office for Health Technology Assessment (1994) Guidelines for economic evaluation of pharmaceuticals: Canada. 1st edn. CCOHTA, Ottawa, Ont
4. Commonwealth of Australia (1990) Guidelines for the pharmaceutical industry in preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Department of Health, Housing and Community Services, Woden. ACT
5. Cottle RW, Begg IS (1988) Effectiveness and costs of antiglaucoma medications. Cutan Ocul Toxicol 7:283-293
6. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, New York
7. Finkler SA (1982) The distinction between costs and charges. Ann Intern Med 96:102-109
8. Gerdtham UG, Hågå A, Karlsson G, Kobelt G, Jönsson B (1996) Observational costing study in open angle primary glaucoma in Sweden and the USA. EFI Research Paper no. 6566, Stockholm School of Economics
9. Gerdtham UG, Williamson T, Hågå A, Kobelt G, Jönsson B (1997) Observational costing study in open angle primary glaucoma: results for Canada. EFI Research Paper no. 6569, Stockholm School of Economics
10. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
11. Heijl A (1989) Effect of IOP on the visual field in ocular hypertension and glaucoma. Int Ophthalmol 13:119-124
12. Hitchings RA (1993). Primary surgery for primary open angle glaucoma - justified or not? Br J Ophthalmol 77:445-448
13. Johannesson M (1996) Theory and methods of economic evaluation of health care. Kluwer Academic, Boston
14. Kobelt G (1996) An introduction to economic evaluation. Office of Health Economics, London
15. Kobelt G, Jönsson L (1998) Modeling cost and cost-effectiveness of new treatments for glaucoma. Int J Med Technol Assessment 15 (in press)
16. Kobelt G, Gerdtham UG, Aim A (1998) Cost of treating primary open angle glaucoma and ocular hypertension. J Glaucoma 7:95-104
17. Quigley HA (1993) Open-angle glaucoma. (review article) New Engl J Med 15:1097-1106
18. PCS Health Systems: Re:Solve 500 data model, glaucoma drug claims, December 1, 1995 to December 31, 1997. Data on file, Pharmacia & Upjohn, Kalamazoo, Mich
19. Rittenhouse B (1996) Uses of models in economic evaluations of medicines and other health technologies. Office of Health Economics, London
20. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making. Med Decision Making 13:322-338
21. Statistisches Jahrbuch der Bundesrepublik Deutschland. Wiesbaden
22. Strahiman E, Tipping MS, Vogel MD (1995) A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol and betaxolol. Arch Ophthalmol 113:1009-1016
23. Tarifverträge (1997) Grunddaten zur kassenärztlichen vertragsärztlichen Versorgung. Kassenärztüche Bundesvereinigung
24. Tielsch JM, Sommer A, Katz J, et al (1991) Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 266:369-374
25. Watson P, Stjernschantz J, The Latanoprost Study Group (1996) A six month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103:126-137